These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 10577464)

  • 1. Newer antiplatelet agents in acute coronary syndromes.
    White HD
    Am Heart J; 1999 Dec; 138(6 Pt 2):S570-6. PubMed ID: 10577464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent antiplatelet drug trials in the acute coronary syndromes. Clinical interpretation of PRISM, PRISM-PLUS, PARAGON A and PURSUIT.
    Alexander JH; Harrington RA
    Drugs; 1998 Dec; 56(6):965-76. PubMed ID: 9878986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina. The PARAGON Investigators. Platelet IIb/IIIa Antagonism for the Reduction of Acute coronary syndrome events in a Global Organization Network.
    Circulation; 1998 Jun; 97(24):2386-95. PubMed ID: 9641689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Promise of combined low-molecular-weight heparin and platelet glycoprotein IIb/IIIa inhibition: results from Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network B (PARAGON B).
    Mukherjee D; Mahaffey KW; Moliterno DJ; Harrington RA; Yadav JS; Pieper KS; Gallup D; Dyke C; Roe MT; Berdan L; Lauer MS; Mänttäri M; White HD; Califf RM; Topol EJ
    Am Heart J; 2002 Dec; 144(6):995-1002. PubMed ID: 12486423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction.
    Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators
    N Engl J Med; 1998 May; 338(21):1488-97. PubMed ID: 9599103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Attenuation of rebound ischemia after discontinuation of heparin therapy by glycoprotein IIb/IIIa inhibition with eptifibatide in patients with acute coronary syndromes: observations from the platelet IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial.
    Lauer MA; Houghtaling PL; Peterson JG; Granger CB; Bhatt DL; Sapp SK; Simoons ML; Harrington RA; Topol EJ; Lincoff AM;
    Circulation; 2001 Dec; 104(23):2772-7. PubMed ID: 11733393
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, and Eptifibatide.
    Batchelor WB; Tolleson TR; Huang Y; Larsen RL; Mantell RM; Dillard P; Davidian M; Zhang D; Cantor WJ; Sketch MH; Ohman EM; Zidar JP; Gretler D; DiBattiste PM; Tcheng JE; Califf RM; Harrington RA
    Circulation; 2002 Sep; 106(12):1470-6. PubMed ID: 12234950
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors.
    Adgey AA
    Am Heart J; 1998 Apr; 135(4):S43-55. PubMed ID: 9539495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of patients with acute coronary syndromes in the United States by platelet glycoprotein IIb/IIIa inhibition. Insights from the platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial.
    Lincoff AM; Harrington RA; Califf RM; Hochman JS; Guerci AD; Ohman EM; Pepine CJ; Kopecky SL; Kleiman NS; Pacchiana CM; Berdan LG; Kitt MM; Simoons ML; Topol EJ
    Circulation; 2000 Sep; 102(10):1093-100. PubMed ID: 10973836
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors.
    Adgey AA
    Eur Heart J; 1998 Apr; 19 Suppl D():D10-21. PubMed ID: 9597518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic use of intravenous eptifibatide in patients undergoing percutaneous coronary intervention: acute coronary syndromes and elective stenting.
    Granada JF; Kleiman NS
    Am J Cardiovasc Drugs; 2004; 4(1):31-41. PubMed ID: 14967064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glycoprotein IIb/IIIa receptor blockade improves outcomes in diabetic patients presenting with unstable angina/non-ST-elevation myocardial infarction: results from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) study.
    Théroux P; Alexander J; Pharand C; Barr E; Snapinn S; Ghannam AF; Sax FL
    Circulation; 2000 Nov; 102(20):2466-72. PubMed ID: 11076818
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of platelet glycoprotein IIb/IIIa receptor blockade with tirofiban on adverse cardiac events in women with unstable angina/non-ST-elevation myocardial infarction (PRISM-PLUS Study).
    Huynh T; Theroux P; Snapinn S; Wan Y;
    Am Heart J; 2003 Oct; 146(4):668-73. PubMed ID: 14564321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The clinical use of the GPIIb/IIIa inhibitors eptifibatide and tirofiban in the treatment of acute coronary syndromes of the "non-ST elevation" type].
    Galli M; Maggioni AP; Vassanelli C; Tavazzi L
    Ital Heart J Suppl; 2000 Feb; 1(2):202-11. PubMed ID: 10731377
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina.
    Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators
    N Engl J Med; 1998 May; 338(21):1498-505. PubMed ID: 9599104
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tirofiban. A review of its use in acute coronary syndromes.
    McClellan KJ; Goa KL
    Drugs; 1998 Dec; 56(6):1067-80. PubMed ID: 9878994
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stroke in patients with acute coronary syndromes: incidence and outcomes in the platelet glycoprotein IIb/IIIa in unstable angina. Receptor suppression using integrilin therapy (PURSUIT) trial. The PURSUIT Investigators.
    Mahaffey KW; Harrington RA; Simoons ML; Granger CB; Graffagnino C; Alberts MJ; Laskowitz DT; Miller JM; Sloan MA; Berdan LG; MacAulay CM; Lincoff AM; Deckers J; Topol EJ; Califf RM
    Circulation; 1999 May; 99(18):2371-7. PubMed ID: 10318656
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of low molecular weight heparins with antiplatelet agents in non-ST elevation acute coronary syndromes: an update.
    Cohen M
    Drugs; 2002; 62(12):1755-70. PubMed ID: 12149045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cigarette smoking status and outcome among patients with acute coronary syndromes without persistent ST-segment elevation: effect of inhibition of platelet glycoprotein IIb/IIIa with eptifibatide. The PURSUIT trial investigators.
    Hasdai D; Holmes DR; Criger DA; Topol EJ; Califf RM; Wilcox RG; Paolasso E; Simoons M; Deckers J; Harrington RA
    Am Heart J; 2000 Mar; 139(3):454-60. PubMed ID: 10689260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term oral platelet glycoprotein IIb/IIIa receptor antagonism with sibrafiban after acute coronary syndromes: study design of the sibrafiban versus aspirin to yield maximum protection from ischemic heart events post-acute coronary syndromes (SYMPHONY) trial. Symphony Steering Committee.
    Newby LK
    Am Heart J; 1999 Aug; 138(2 Pt 1):210-8. PubMed ID: 10426831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.